Physician profile
Gregory K Lemite
NPI 1528027224
$8,211.63
in general payments reported to CMS, 2019-2025
31 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $843 · 2021: $1,275 · 2022: $1,063 · 2023: $1,211 · 2024: $1,634 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,109.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $797.54 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $771.44 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $519.99 | 2019-2025 | |
| Janssen Biotech, INC. | $474.28 | 2020-2025 | Stelara, Tremfya |
| Ferring Pharmaceuticals INC. | $295.69 | 2021-2024 | Rebyota |
| Genzyme Corporation | $192.19 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $178.70 | 2020-2023 | |
| Celgene Corporation | $177.33 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $165.28 | 2020-2021 | |
| Ardelyx, INC. | $159.37 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $147.54 | 2020-2025 | Linzess |
| Enterra Medical, INC. | $120.70 | 2023-2025 | |
| Penumbra, INC. | $112.56 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $111.64 | 2024-2025 | Iqirvo, Bylvay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $101.28 | 2019-2025 | |
| Celltrion USA INC. | $93.51 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $89.09 | 2020-2024 | Givlaari |
| Merck Sharp & Dohme LLC | $88.16 | 2019-2022 | |
| Braintree Laboratories, INC. | $86.55 | 2019-2023 | Sutab |
| Aimmune Therapeutics, INC. | $79.07 | 2025 | Zenpep, Vowst |
| Qol Medical, LLC | $71.61 | 2021 | |
| Concordia Pharmaceuticals INC. | $68.70 | 2019 | |
| Lilly USA, LLC | $43.57 | 2023-2025 | Omvoh |
| Ethicon US, LLC | $40.25 | 2021 | |
| Phadia US INC. | $31.08 | 2022-2024 | Immunocap |
| Daiichi Sankyo INC. | $24.15 | 2023 | Injectafer |
| Shire North American Group INC | $21.28 | 2019 | |
| Evoke Pharma, INC. | $15.30 | 2020 | |
| Allergan, INC. | $13.47 | 2020 | |
| Meridian Bioscience INC. | $11.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lemite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.